Search hospitals > Florida > Orlando
Orlando Health Cancer Institute
Claim this profileOrlando, Florida 32806
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Tumors
Conducts research for Melanoma
Conducts research for Recurrence
239 reported clinical trials
23 medical researchers
Summary
Orlando Health Cancer Institute is a medical facility located in Orlando, Florida. This center is recognized for care of Cancer, Breast Cancer, Tumors, Melanoma, Recurrence and other specialties. Orlando Health Cancer Institute is involved with conducting 239 clinical trials across 393 conditions. There are 23 research doctors associated with this hospital, such as Amy Smith, MD, Sajeve S. Thomas, Jennifer Tseng, MD, and Daniel Landau.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Amy Smith, MDArnold Palmer Hospital for Children6 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
54 reported clinical trials
107 drugs studied
Sajeve S. ThomasOrlando Health Cancer Institute7 years of reported clinical research
Expert in Melanoma
Studies Cancer
20 reported clinical trials
31 drugs studied
Jennifer Tseng, MDCity of Hope9 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
9 reported clinical trials
28 drugs studied
Daniel LandauOrlando Health Cancer Institute5 years of reported clinical research
Studies Prostate Cancer
Studies Renal Cell Carcinoma
6 reported clinical trials
24 drugs studied
Clinical Trials running at Orlando Health Cancer Institute
Breast Cancer
Gastroesophageal Junction Adenocarcinoma
Non-Small Cell Lung Cancer
Esophageal Adenocarcinoma
Melanoma
Esophageal Carcinoma
Lung Cancer
Prostate Cancer
Bladder Carcinoma
Squamous Cell Carcinoma
Giredestrant + Everolimus
for Advanced or Metastatic Breast Cancer
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.
Recruiting2 awards Phase 37 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Orlando Health Cancer Institute?
Orlando Health Cancer Institute is a medical facility located in Orlando, Florida. This center is recognized for care of Cancer, Breast Cancer, Tumors, Melanoma, Recurrence and other specialties. Orlando Health Cancer Institute is involved with conducting 239 clinical trials across 393 conditions. There are 23 research doctors associated with this hospital, such as Amy Smith, MD, Sajeve S. Thomas, Jennifer Tseng, MD, and Daniel Landau.